MAPK3 and esophageal squamous cell carcinoma: In esophageal squamous cell carcinoma, the FXR agonist GW4064 impaired esophageal squamous cell carcinoma proliferation and migration by inducing apoptosis and cell-cycle arrest and suppressing phosphorylation of ERK1/2 protein expression [17].